Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02357459 · ClinicalTrials.gov registry record · Phase 3
Study of FX006 for the Treatment of Pain in Patients With Osteoarthritis of the Knee
A Phase 3 study of Osteoarthritis of the Knee, sponsored by Pacira Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 486
- Enrollment target
- 20
- Study locations
NCT02357459: Completed Phase 3 study of Osteoarthritis of the Knee, sponsored by Pacira Pharmaceuticals.
NCT02357459 is a Phase 3 study of Osteoarthritis of the Knee that has completed, run by Pacira Pharmaceuticals. The registered enrollment target is 486 participants, above the 182-participant average among 16 other Osteoarthritis of the Knee trials with a reported enrollment target (167% higher). The trial reports 20 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02357459, a Phase 3 study of Osteoarthritis of the Knee, has completed, sponsored by Pacira Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 486 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study was to assess the safety and efficacy of FX006 for the treatment of pain in patients with osteoarthritis of the knee.
Primary Outcome
The pain intensity score is measured using an 11-point numeric rating scale (NRS), where ) indicates "no pain" and 10 indicates "pain as bad as you can imagine."
Conditions Studied
Interventions
- DRUG Placebo
- DRUG FX006
- DRUG TCA IR 40
Study Locations (20)
Florida
- - Atlantis
- - DeLand
- - Hialeah
- - Sarasota
- - West Palm Beach
California
- - Anaheim
- - Canoga Park
- - North Hollywood
- - San Diego
North Carolina
- - Cary
- PMG Research of Cary - Cary
- - Charlotte
Arizona
- - Phoenix
- - Tucson
Tennessee
- PMG Research of Knoxville - Knoxville
- PMG Research of Knoxville - Knoxville
Colorado
- - Denver
Kansas
- - Prairie Village
New Mexico
- - Albuquerque
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 486 participants |
| Start Date | 2015-01 |
| Est. Completion | 2016-01 |
| Phase | Phase 3 |
What the finished NCT02357459 record still lists
NCT02357459 is an interventional study that assigns participants to a tested intervention. The registered 486 participants enrollment target is mid-sized for trials with a published cap, above the 182-participant average among 16 other Osteoarthritis of the Knee trials with a reported enrollment target (167% higher).
The record links to 1 condition, with Osteoarthritis of the Knee appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT02357459 names 20 study sites across 9 states, led by Florida, California, North Carolina.
Frequently Asked Questions
What is clinical trial NCT02357459 about?
NCT02357459 is a clinical study titled "Study of FX006 for the Treatment of Pain in Patients With Osteoarthritis of the Knee". The purpose of this study was to assess the safety and efficacy of FX006 for the treatment of pain in patients with osteoarthritis of the knee.
What is the current status of trial NCT02357459?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 486 participants. The study started on 2015-01. Estimated completion is 2016-01.
What conditions does trial NCT02357459 study?
This clinical trial studies the following conditions: Osteoarthritis of the Knee.
What interventions are being tested in trial NCT02357459?
The interventions under investigation include: Placebo (DRUG), FX006 (DRUG), TCA IR 40 (DRUG).
Who is sponsoring clinical trial NCT02357459?
This trial is sponsored by Pacira Pharmaceuticals, which has 88 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02357459 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, Florida, Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Osteoarthritis of the Knee
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02357459's enrollment target sits among peer trials
486 2nd of 16 the highest of 16 other Osteoarthritis of the Knee trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Osteoarthritis of the Knee trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Pragmatic Trial to Determine the Benefit of Behaviorally Enhanced Exercise Incentives and Corticosteroid Injections in Osteoarthritis of the Knee Marching On for Veterans With Osteoarthritis of the Knee
ACTIVE NOT RECRUITING · Phase 3
-
Extended and Controlled Release Liposomal Formulated Dexamethasone for Chronic Knee OA Pain
COMPLETED · Phase 3
-
Study to Assess the Safety of Repeat Administration of FX006 Administered to Patients With Osteoarthritis of the Knee
COMPLETED · Phase 3
-
Cannabinoid Interactions With Central and Peripheral Pain Mechanisms in Osteoarthritis of the Knee
RECRUITING · Phase 2
-
Bone Marrow Aspirate Concentrate (BMAC) vs Corticosteroid Injection
RECRUITING · NA
-
Home-Based Leg Dexterity Trainer for Management of Knee Osteoarthritis
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06420531 · 486 participants · NA
Milk And Growth In Children (MAGIC) Born Very Preterm: A Randomized Trial
- NCT07097142 · 486 participants · Phase 3
Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients Receiving the Usual Chemotherapy Treatment for Bladder Cancer, ARCHER Study
- NCT06948435 · 487 participants · Phase 3
A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL1
- NCT06952530 · 487 participants · Phase 3
A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL2
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia